Artio closes $28M as it scales to save lives; latest funding brings Prairie Village startup’s investments to $74M
June 16, 2022 | Startland News Staff
Another hefty funding round for Artio Medical is expected to launch the startup’s commercial sales team in the U.S. and continue development of its best-in-class product pipeline, said founder Nicholas Franano.
Artio, a medical device company developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, on Thursday announced the closing of $28 million in oversubscribed Series A2 and Series A3 financing, bringing the total amount raised to date to $74 million.
Funds will be used to support U.S. commercialization efforts for the recently cleared Solus Gold Embolization Device and to accelerate the development of Artio’s broad portfolio of products, including expanding the company’s engineering and manufacturing capabilities, Franano said in a press release.
Click here to read more about Artio’s $12 million funding infusion in 2021.
“We would like to thank our existing investors for their continued strong support and also welcome a new group of investors to Artio,” said Joseph McConnell, vice president of finance and business operations at Artio.
“We have the opportunity to do something really special here, to bring a new generation of medical devices to market with the potential to save lives, reduce disability, and improve the quality of life for millions of people,” McConnell continued. “This new capital will help Artio expand our team and scale our operations to deliver on that mission.”
Artio is currently developing ten products for the peripheral vascular market, including the Solus Gold and Solus Flex Embolization Devices for peripheral vessel occlusion and the Amplifi Vein Dilation System which is designed to prepare hemodialysis patients for successful arteriovenous fistula vascular access site creation.
Artio is also currently developing four products for the neurovascular market, including the Endura Embolization System comprising a detachable balloon and coils for the treatment of saccular brain aneurysms.
Click here to learn more about Artio’s portfolio of products.
2022 Startups to Watch
stats here
Related Posts on Startland News
JQ Sirls is the king of his own universe; his new book puts a distinctly Black hero at the center of it
JQ Sirls started popping through the multiverse as a child; escaping through various worlds and alternate realities via stories like “Where the Wild Things Are,” “Peter Pan,” and “The Wizard of Oz” — as well as magical realms he created himself. “Those are my DNA,” said Sirls, a Kansas City-based author, artist and the entrepreneur behind…
His KC theater shines spotlight on queer voices; How one playwright is giving stage time to a new wave of talent
Kansas City’s theater scene should be a safe and comfortable space, said Kevin King, detailing his effort to specifically provide a place where queer voices can not only feel heard, but celebrated. “Since 2019, we’ve been basically gay all the time,” said King, producing artistic director at Whim Productions, an LGBTQ+ theater company with a…
Premiere Kansas City startup acquired by Texas-based IoT leader in proptech industry
The acquisition of Crossroads-built Homebase by Lone Star State smart home innovator Quext brings together two of the most disruptive companies in the space, said Blake Miller, founder of the premiere Kansas City startup. The move — creating a single source for multifamily operators to get the best-in-class smart community and managed WiFi solutions their…
Starlight wants to add a canopy to KC’s famed outdoor theater; Here’s what else its $40M capital campaign would bring
Editor’s note: The following story was published by KCUR, Kansas City’s NPR member station, and a fellow member of the KC Media Collective. Click here to read the original story or here to sign up for KCUR’s email newsletter. If fully funded, the campaign will make capital improvements across the entire Starlight campus — including the construction of a production…